Source and scope
This summary is bounded to the recommendations, population and decisions covered by Guideline No. 426: Hypertensive Disorders of Pregnancy. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC 426
Source-attributed clinical priorities
- Confirm blood pressure with appropriate pregnancy technique and assess symptoms, urine protein, platelets, kidney and liver involvement and fetal wellbeing.
- Distinguish chronic, gestational and preeclampsia phenotypes because prevention, surveillance and timing of birth differ.
- Escalate severe hypertension or maternal or fetal severe features urgently and plan postpartum blood-pressure and cardiovascular follow-up.
- Use correctly sized, repeated blood-pressure measurement and interpret it with gestational age and end-organ features.
sources for this section:SOGC 426
Practical assessment and management workflow
1
Confirm pregnancy dating and distinguish chronic, gestational and preeclamptic presentations.
2
Assess headache, visual symptoms, epigastric pain, edema, reflexes, urine protein, blood count, kidney and liver tests.
3
Coordinate fetal growth and wellbeing surveillance with maternal treatment through obstetric care.
4
Plan timing and place of birth and postpartum blood-pressure and long-term cardiovascular follow-up.
sources for this section:SOGC 426
Safety, red flags and urgent escalation
- Severe hypertension, neurologic symptoms, pulmonary edema, abnormal liver or platelet findings or fetal concern needs urgent obstetric assessment.
- Treat eclampsia as an emergency and follow the local magnesium and delivery protocol.
- Avoid renin-angiotensin system blockers during pregnancy.
sources for this section:SOGC 426
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC 426
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC 426
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Society of Obstetricians and Gynaecologists of CanadaGuideline No. 426: Hypertensive Disorders of Pregnancyaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.